Please ensure Javascript is enabled for purposes of website accessibility

Why Cara Therapeutics Stock Is Soaring Higher Today

By Keith Speights - Apr 6, 2021 at 10:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech stock is being added to an important small-cap index.

What happened

Shares of Cara Therapeutics (CARA 2.87%) were soaring 13.1% higher as of 10:45 a.m. EDT on Tuesday. The big gain came after S&P Global division S&P Dow Jones Indices announced that Cara will replace MTS Systems in the S&P SmallCap 600 index

So what

The nice jump for Cara today makes sense. S&P Dow Jones Indices' news means that any mutual funds or exchange-traded funds (ETFs) that track the S&P SmallCap 600 index will load up on shares of Cara Therapeutics. 

Scientist holding two test tubes

Image source: Getty Images.

However, the boost from being added to this index will only be a temporary one. After the funds have bought shares of Cara, the biotech's fortunes will depend on what happens with its business.

There's reason to be optimistic on that front. Cara and its partner Vifor Pharma announced on March 8 that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Korsuva injection in treating moderate to severe pruritis (itching) in hemodialysis patients. The FDA also granted Priority Review to the NDA, which will shorten the review process.

Now what

The FDA should make its approval decision for Korsuva by Aug. 23. That's not the only potential catalyst for Cara on the way, though. The company expects to report top-line data from its phase 2 study of an oral version of Korsuva in treating atopic dermatitis within the next couple of months.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$8.24 (2.87%) $0.23
S&P Global Inc. Stock Quote
S&P Global Inc.
SPGI
$360.64 (2.32%) $8.17
MTS Systems Corporation Stock Quote
MTS Systems Corporation
MTSC

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.